Free Trial
→ You cannot escape this reality (From Porter & Company) (Ad)tc pixel Free AMPE Stock Alerts

Ampio Pharmaceuticals (AMPE) Competitors

Ampio Pharmaceuticals logo
$0.18 0.00 (0.00%)
As of 05/22/2026
Compare

AMPE vs. CMND, PRPH, PRFX, VRAX, and BPTSY

Should you buy Ampio Pharmaceuticals stock or one of its competitors? MarketBeat compares Ampio Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ampio Pharmaceuticals include Clearmind Medicine (CMND), ProPhase Labs (PRPH), PainReform (PRFX), Virax Biolabs Group (VRAX), and Biophytis (BPTSY). These companies are all part of the "pharmaceutical products" industry.

How does Ampio Pharmaceuticals compare to Clearmind Medicine?

Ampio Pharmaceuticals (NYSE:AMPE) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Ampio Pharmaceuticals has a beta of 5.96, indicating that its stock price is 496% more volatile than the broader market. Comparatively, Clearmind Medicine has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Clearmind Medicine is trading at a lower price-to-earnings ratio than Ampio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A
Clearmind MedicineN/AN/A-$3.86M-$19.72N/A

Ampio Pharmaceuticals' return on equity of 0.00% beat Clearmind Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Ampio PharmaceuticalsN/A N/A N/A
Clearmind Medicine N/A -207.53%-100.70%

In the previous week, Clearmind Medicine had 6 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 6 mentions for Clearmind Medicine and 0 mentions for Ampio Pharmaceuticals. Clearmind Medicine's average media sentiment score of 0.24 beat Ampio Pharmaceuticals' score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the news media.

Company Overall Sentiment
Ampio Pharmaceuticals Neutral
Clearmind Medicine Neutral

Summary

Ampio Pharmaceuticals beats Clearmind Medicine on 6 of the 10 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to ProPhase Labs?

ProPhase Labs (NASDAQ:PRPH) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProPhase Labs
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Ampio Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Ampio Pharmaceuticals has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Ampio Pharmaceuticals' return on equity of 0.00% beat ProPhase Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
ProPhase Labs-825.01% -482.05% -88.90%
Ampio Pharmaceuticals N/A N/A N/A

In the previous week, ProPhase Labs' average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
ProPhase Labs Neutral
Ampio Pharmaceuticals Neutral

ProPhase Labs has a beta of 0.15, meaning that its share price is 85% less volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, meaning that its share price is 496% more volatile than the broader market.

Ampio Pharmaceuticals has lower revenue, but higher earnings than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than Ampio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProPhase Labs$5.06M0.13-$53.36M-$3.90N/A
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A

9.4% of ProPhase Labs shares are owned by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 9.6% of ProPhase Labs shares are owned by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Ampio Pharmaceuticals beats ProPhase Labs on 6 of the 11 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to PainReform?

Ampio Pharmaceuticals (NYSE:AMPE) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ampio Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
PainReform
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Ampio Pharmaceuticals has a beta of 5.96, indicating that its share price is 496% more volatile than the broader market. Comparatively, PainReform has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market.

PainReform has higher revenue and earnings than Ampio Pharmaceuticals. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A
PainReform$20K29.80-$5.02M-$736.66N/A

Company Net Margins Return on Equity Return on Assets
Ampio PharmaceuticalsN/A N/A N/A
PainReform N/A N/A N/A

In the previous week, PainReform had 1 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 1 mentions for PainReform and 0 mentions for Ampio Pharmaceuticals. Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled PainReform'saverage media sentiment score.

Company Overall Sentiment
Ampio Pharmaceuticals Neutral
PainReform Neutral

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 37.3% of PainReform shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Comparatively, 34.4% of PainReform shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

PainReform beats Ampio Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Virax Biolabs Group?

Virax Biolabs Group (NASDAQ:VRAX) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Virax Biolabs Group currently has a consensus target price of $1.00, indicating a potential upside of 260.36%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe Virax Biolabs Group is more favorable than Ampio Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virax Biolabs Group
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Ampio Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Virax Biolabs Group has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, indicating that its stock price is 496% more volatile than the broader market.

Virax Biolabs Group has higher revenue and earnings than Ampio Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virax Biolabs Group$10K120.44-$6.06MN/AN/A
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A

Company Net Margins Return on Equity Return on Assets
Virax Biolabs GroupN/A N/A N/A
Ampio Pharmaceuticals N/A N/A N/A

In the previous week, Virax Biolabs Group had 1 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 1 mentions for Virax Biolabs Group and 0 mentions for Ampio Pharmaceuticals. Virax Biolabs Group's average media sentiment score of 1.24 beat Ampio Pharmaceuticals' score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the media.

Company Overall Sentiment
Virax Biolabs Group Positive
Ampio Pharmaceuticals Neutral

8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by company insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Virax Biolabs Group beats Ampio Pharmaceuticals on 9 of the 10 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Biophytis?

Ampio Pharmaceuticals (NYSE:AMPE) and Biophytis (NASDAQ:BPTSY) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A
BiophytisN/AN/A-$18.43MN/AN/A

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company Overall Sentiment
Ampio Pharmaceuticals Neutral
Biophytis Neutral

Company Net Margins Return on Equity Return on Assets
Ampio PharmaceuticalsN/A N/A N/A
Biophytis N/A N/A N/A

5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by insiders. Comparatively, 3.7% of Biophytis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Ampio Pharmaceuticals has a beta of 5.96, suggesting that its share price is 496% more volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, suggesting that its share price is 146% more volatile than the broader market.

Summary

Ampio Pharmaceuticals beats Biophytis on 3 of the 4 factors compared between the two stocks.

Get Ampio Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMPE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMPE vs. The Competition

Export
MetricAmpio PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$208K$927.43M$6.46B$23.20B
Dividend YieldN/A4.84%2.76%4.10%
P/E Ratio-0.021.4621.0030.65
Price / SalesN/A119.63562.1824.50
Price / CashN/A20.0743.4925.12
Price / Book0.057.5910.414.74
Net Income-$8.63M-$3.64M$3.57B$1.07B
7 Day PerformanceN/A3.01%6.40%2.36%
1 Month PerformanceN/A76.62%3.54%1.58%
1 Year PerformanceN/A126.61%34.14%28.42%

Ampio Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMPE
Ampio Pharmaceuticals
N/A$0.18
flat		N/AN/A$208KN/AN/A20
CMND
Clearmind Medicine
1.1488 of 5 stars		$0.52
-3.7%		N/A-99.4%$810KN/AN/AN/A
PRPH
ProPhase Labs
N/A$0.12
-9.9%		N/A-96.6%$720K$5.06MN/A130
PRFX
PainReform
0.574 of 5 stars		$1.61
-3.6%		N/A-84.9%$670K$20KN/A4
VRAX
Virax Biolabs Group
3.2893 of 5 stars		$0.14
-3.7%		$1.00
+616.3%		-72.8%$630K$10KN/A5

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:AMPE) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel